BETA

IPO registrations (S-1, F-1) · Registrants

PhaseBio Pharmaceuticals Inc

SEC CIK
1169245 · filings on EDGAR ↗
Former names
Phase Biosciences Inc (2006–2008); DT BIOSCIENCES INC (2002–2004)
Registration
Form S-1, first filed 2018-09-21, last 2019-04-09; 2 initial registrations, 2 amendments
Outcome
Final prospectus filed 2018-10-19; declared effective 2018-10-17
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
1 GREAT VALLEY PARKWAY, SUITE 30, Malvern, PA 19355
EIN
03-0375697
EDGAR entity type
operating
Insiders and CEO pay
PhaseBio Pharmaceuticals Inc on the corporate pages

Offering terms

Final price
$5.00 per share (424B4 filed 2018-10-19, an initial public offering)
Shares sold
9,200,000
Gross proceeds
$46,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol PHAS
Lead underwriters
Citigroup; Cowen (2,944,000 shares); Stifel (1,702,000 shares)
Syndicate
Needham & Company (736,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 10

FiledFormWhat it isName as filedEDGAR
2018-09-21S-1S-1 (registration)PhaseBio Pharmaceuticals Inc0001193125-18-280007 ↗
2018-10-05S-1/AS-1/A (amendment)PhaseBio Pharmaceuticals Inc0001193125-18-294730 ↗
2018-10-15S-1/AS-1/A (amendment)PhaseBio Pharmaceuticals Inc0001193125-18-298749 ↗
2018-10-17EFFECTEFFECT (declared effective)PhaseBio Pharmaceuticals Inc9999999995-18-002647 ↗
2018-10-19424B4424B4 (final prospectus)PhaseBio Pharmaceuticals Inc0001193125-18-302148 ↗
2019-04-09S-1S-1 (registration)PhaseBio Pharmaceuticals Inc0001193125-19-101668 ↗
2019-04-11S-1MEFS-1MEF (added securities)PhaseBio Pharmaceuticals Inc0001193125-19-104225 ↗
2019-04-11EFFECTEFFECT (declared effective)PhaseBio Pharmaceuticals Inc9999999995-19-000684 ↗
2019-04-12424B4424B4 (final prospectus)PhaseBio Pharmaceuticals Inc0001193125-19-105228 ↗
2020-01-08EFFECTEFFECT (declared effective)PhaseBio Pharmaceuticals Inc9999999995-20-000039 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2018-10-15S-1/Aregistration statement$9.66--0primary document; price linedocument ↗
2018-10-19424B4final prospectus$5.009,200,000$46,000,000Nasdaq PHAS4primary document; price sentence, shares headline, proceeds computed, underwriting table 3, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Arnold Susan ElizabethOfficerSVP, Technical Operations; VP, Preclinical and Chem; VP, Preclinical and Chem.132018–2022
ASTRAZENECA PLCTenPercentOwner22018
Ballance David JamesOfficerVP, Research and Sci. Affairs62018–2020
BARRETT M JAMESTenPercentOwner22018
BARRIS PETER JTenPercentOwner22018
BASKETT FORESTTenPercentOwner32018–2022
Catalysta Ventures, LLCTenPercentOwner22018
Crumpler JohnTenPercentOwner22018
Hatteras Venture Advisors III, LLCTenPercentOwner22018
Hatteras Venture Affiliates III LpTenPercentOwner22018
Hatteras Venture Partners I, LPTenPercentOwner22018
Hatteras Ventures Partners III LPTenPercentOwner22018
Hutson Nancy JDirector112018–2023
INGRAM ROBERT ALEXANDERTenPercentOwner22018
KERINS PATRICK JTenPercentOwner32018–2022
Klein Peter JustinDirector62018–2021
Lee John SangOfficerChief Medical Officer52018–2022
LEE KENNETH B JRTenPercentOwner22018
Loewy Caroline MDirector72018–2023
MOTT DAVID MTenPercentOwner22018
Mow Jonathan PDirector,OfficerChief Executive Officer192018–2022
Mukhopadhyay BibhashDirector32018–2019
NEA 13 GP, LtdTenPercentOwner32018–2022
NEA Partners 13, Limited PartnershipTenPercentOwner32018–2022
NEW ENTERPRISE ASSOCIATES 13 LPTenPercentOwner32018–2022
Reed Douglas MDTenPercentOwner22018
Rivers TyrellDirector12018
SANDELL SCOTT DTenPercentOwner32018–2022
Sharp John POfficerCFO and Secretary; Chief Financial Officer162018–2022
Thorp ClayDirector; Director,TenPercentOwner142018–2023
TUFTS LINDADirector32018–2019
Venture Capital Multiplier FundTenPercentOwner22018
Viswanathan RaviTenPercentOwner22018
York MichaelOfficerVP, Corporate Development72018–2021
Zeneca, Inc.TenPercentOwner22018
HARRIGAN EDMUNDDirector82018–2023
van den Broek RichardDirector72019–2023
Hanson KristopherOfficerSVP and General Counsel; Vice President, Head of Legal; VP, Head of Legal92019–2022
Burkhardt GlenOfficerSVP of Human Resources; VP, Human Resources82020–2022
Sapir AlexDirector62020–2023
Humphries William D.Director52021–2023
Birchall JonathanOfficerChief Commercial Officer42021–2022

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2018-09-10PhaseBio Pharmaceuticals IncPharmaceuticals$32,125,000$25,998,130201
2017-01-31PhaseBio Pharmaceuticals IncBiotechnology$7,875,000$6,615,00091
2015-03-12PhaseBio Pharmaceuticals IncBiotechnology$42,000,000$21,000,00092

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationPhasebio Pharmaceuticals, Inc.PAState business registriesname and state
Form D issuerPhaseBio Pharmaceuticals IncPAForm D private offeringsCIK (EXACT)
Lobbying clientPHASEBIO PHARMACEUTICALS, INCPAFederal lobbying (LDA)name and state
Patent assigneePHASEBIO PHARMACEUTICALS, INC.PAPatents (USPTO)name and state
SEC filerPhaseBio Pharmaceuticals IncSEC filers (EDGAR)CIK (EXACT)
Trademark ownerPhaseBio Pharmaceuticals, Inc.PATrademarks (USPTO)name and state
Form 5500 plan sponsorPHASEBIO PHARMACEUTICALS, INC.EIN (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, PA first:

More with this interest.

In other datasets, the same topic (Health) in PA:

Interests: Pharmaceutical Preparations · Health